Key result
Laropiprant in single doses up to 900 mg and multiple doses up to 450 mg was well tolerated in healthy men, exhibiting dose-proportional pharmacokinetics and target engagement with DP1.
Why the study?
What are the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of laropiprant in healthy male volunteers?
RCT
Double-blind
What are the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of laropiprant in healthy male volunteers?
Laropiprant demonstrates favorable safety, dose-proportional pharmacokinetics, and effective DP1 target engagement in healthy male volunteers without clinically significant effects on bleeding times at doses up to 200 mg.
No takes yet. Share an insight, caveat, or question.
Well tolerated up to 900 mg single/450 mg multiple doses; extends safety and PK data for DP1 antagonism in trials.
Lai et al. (2007) conducted an RCT in Healthy. Laropiprant vs. Placebo was evaluated on Safety, tolerability, pharmacokinetics, and pharmacodynamics. Laropiprant in single doses up to 900 mg and multiple doses up to 450 mg was well tolerated in healthy men, exhibiting dose-proportional pharmacokinetics and target engagement with DP1.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: